WuXi Biologics and I-Mab Biopharma have entered into a long-term strategic partnership focused on biologics process development, clinical and commercial manufacturing of I-Mab’s pipeline of biologics in immuno-oncology and auto-immune diseases.   I-Mab will leverage WuXi Bio’s capabilities for CMC development for at least five programs and commercial manufacturing of at least one program for its proprietary monoclonal antibody, bispecific antibody and fusion protein pipelines, repr...